MX2020007312A - Regimenes de dosificacion superior de g1t38. - Google Patents

Regimenes de dosificacion superior de g1t38.

Info

Publication number
MX2020007312A
MX2020007312A MX2020007312A MX2020007312A MX2020007312A MX 2020007312 A MX2020007312 A MX 2020007312A MX 2020007312 A MX2020007312 A MX 2020007312A MX 2020007312 A MX2020007312 A MX 2020007312A MX 2020007312 A MX2020007312 A MX 2020007312A
Authority
MX
Mexico
Prior art keywords
dosage regimes
superior
ratio
superior dosage
mean auc
Prior art date
Application number
MX2020007312A
Other languages
English (en)
Inventor
Jay Copeland Strum
Andrew Beelen
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of MX2020007312A publication Critical patent/MX2020007312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un régimen de dosificación oral humana de G1T38 que ofrece una relación (media del AUC(0-24),ss(h*ng/mL))/(dosis (mg)) menor que 5 y/o una relación (media del AUC(0-24),ss (h*ng/mL))/(recuento absoluto de neutrófilos (células/mm3)) =1,25 en el día 22 de una dosificación.
MX2020007312A 2018-01-08 2019-01-08 Regimenes de dosificacion superior de g1t38. MX2020007312A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862614952P 2018-01-08 2018-01-08
US201862679575P 2018-06-01 2018-06-01
US201962788017P 2019-01-03 2019-01-03
PCT/US2019/012720 WO2019136451A1 (en) 2018-01-08 2019-01-08 G1t38 superior dosage regimes

Publications (1)

Publication Number Publication Date
MX2020007312A true MX2020007312A (es) 2021-01-08

Family

ID=67143921

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007312A MX2020007312A (es) 2018-01-08 2019-01-08 Regimenes de dosificacion superior de g1t38.
MX2024013788A MX2024013788A (es) 2018-01-08 2020-07-13 Regimenes de dosificacion superior de g1t38

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024013788A MX2024013788A (es) 2018-01-08 2020-07-13 Regimenes de dosificacion superior de g1t38

Country Status (17)

Country Link
US (3) US11357779B2 (es)
EP (1) EP3738084A4 (es)
JP (1) JP2021509680A (es)
KR (1) KR20200108867A (es)
CN (1) CN111837146B (es)
AU (2) AU2019205821C1 (es)
BR (1) BR112020013915A2 (es)
CA (1) CA3087570A1 (es)
CO (1) CO2020008825A2 (es)
IL (1) IL275708A (es)
MX (2) MX2020007312A (es)
MY (1) MY205589A (es)
PE (1) PE20210121A1 (es)
PH (1) PH12020551050A1 (es)
RU (1) RU2020123665A (es)
SG (1) SG11202005937QA (es)
WO (1) WO2019136451A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968290T3 (da) * 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
MX2020007312A (es) * 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CA3188821A1 (en) * 2020-08-13 2022-02-17 Lars ANDERS Combination therapy
CA3210023A1 (en) * 2021-01-29 2022-08-04 Zhuhai United Laboratories Co., Ltd. Oral preparation containing jak inhibitors or salts or crystal forms thereof, and preparation method and application thereof
UY39673A (es) * 2021-03-17 2022-10-31 Amgen Inc Pauta posológica de sotorasib
TW202310841A (zh) * 2021-09-03 2023-03-16 瑞士商諾華公司 用於治療多發性硬化症之ｌｏｕ０６４
IL317147A (en) * 2022-06-16 2025-01-01 Japan Tobacco Inc Dihydroxyoxadiazinone compound and its pharmaceutical use

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561516A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
EP2320903B1 (en) 2008-07-29 2017-01-18 Nerviano Medical Sciences S.r.l. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JP2012504646A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
JP5826772B2 (ja) * 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
KR102051881B1 (ko) 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
EP2640394A4 (en) 2010-11-17 2015-02-25 Univ North Carolina PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
CN103635189B (zh) 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
CN103702990B (zh) 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014022830A2 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
HK1222766A1 (zh) * 2013-03-15 2017-07-14 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2014144596A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
JP6479812B2 (ja) 2013-08-28 2019-03-06 ノバルティス アーゲー 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
US20160257688A1 (en) 2013-10-24 2016-09-08 Francis Xavier Tavares Process for Synthesis of Lactams
WO2015084892A1 (en) 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
AU2014368927B2 (en) 2013-12-20 2018-10-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
US9796701B2 (en) 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
CN106065016B (zh) 2015-04-22 2019-03-12 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
US20180243304A1 (en) 2015-08-28 2018-08-30 Novartis Ag Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
WO2017193141A1 (en) 2016-05-06 2017-11-09 Siyuan Zhang Prognosis biomarkers and anti-tumor compositions of targeted therapeutic treatments for triple negative breast cancer
LT3474841T (lt) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ krūties vėžio gydymo būdai
CN109803684B (zh) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
AU2017359333B2 (en) 2016-11-08 2024-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
EP3541389A1 (en) 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
WO2018156812A1 (en) 2017-02-22 2018-08-30 G1 Therapeutics, Inc. Treatment of egfr-driven cancer with fewer side effects
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
US20200108066A1 (en) 2017-03-30 2020-04-09 Shorn Goel Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
AU2018282901A1 (en) 2017-06-12 2020-01-16 Syros Pharmaceuticals, Inc. Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (CDK7)
GB201709417D0 (en) 2017-06-14 2017-07-26 Inst Of Cancer Research: Royal Cancer Hospital Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
JP2020525427A (ja) 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
CN109982701B (zh) 2017-06-21 2022-04-12 江苏恒瑞医药股份有限公司 SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
FI3645001T3 (fi) * 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
MX2020001253A (es) 2017-08-03 2020-07-13 Novartis Ag Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina.
WO2019108589A1 (en) 2017-11-30 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
MX2020007312A (es) * 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.

Also Published As

Publication number Publication date
JP2021509680A (ja) 2021-04-01
CN111837146B (zh) 2024-10-15
BR112020013915A2 (pt) 2020-12-01
EP3738084A1 (en) 2020-11-18
NZ765617A (en) 2025-10-31
SG11202005937QA (en) 2020-07-29
PH12020551050A1 (en) 2021-08-23
RU2020123665A (ru) 2022-02-10
IL275708A (en) 2020-08-31
US20260014160A1 (en) 2026-01-15
AU2019205821A1 (en) 2020-07-09
US12364697B2 (en) 2025-07-22
US20230149406A1 (en) 2023-05-18
AU2024205055A1 (en) 2024-08-15
US20200405721A1 (en) 2020-12-31
US11357779B2 (en) 2022-06-14
MY205589A (en) 2024-10-28
CO2020008825A2 (es) 2020-07-31
WO2019136451A1 (en) 2019-07-11
CA3087570A1 (en) 2019-07-11
AU2019205821C1 (en) 2025-02-13
MX2024013788A (es) 2024-12-06
CN111837146A (zh) 2020-10-27
PE20210121A1 (es) 2021-01-19
AU2019205821B2 (en) 2024-07-18
KR20200108867A (ko) 2020-09-21
EP3738084A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
PH12020551050A1 (en) G1t38 superior dosage regimes
MX2024005855A (es) Procedimientos para tratar el cancer.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
WO2019046568A8 (en) High concentration dosage forms of pridopidine
GEP20227407B (en) Contraceptive composition with reduced cardiovascular effects
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
ZA202210640B (en) Deuterated oxophenylarsine compound and use thereof
PH12022551468A1 (en) Compounds active towards nuclear receptors
WO2022081310A3 (en) Inhaled pde-v inhibitor drugs
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2023007741A (es) Formulaciones de upadacitinib de liberacion prolongada.
MX354080B (es) Tratamiento de la esclerosis multiple (em) con campath 1h.
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
MX2025007170A (es) Esquema de dosificacion de una dispersion solida de un inhibidor de her2
NZ765617B2 (en) G1t38 superior dosage regimes
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
MY206658A (en) Pharmaceutical composition containing acetominophen and ibuprofen
MX2023013144A (es) Tableta erosionable.
EA202091507A1 (ru) Преимущественные режимы дозирования g1t38
MD20160131A2 (ro) Compus de tiacumicină şi regim de tratament asociat
ZA202401265B (en) Progestogen-only oral contraception
MX2025009380A (es) Polipéptido y sus derivados, composición que comprende los mismos, y uso de los mismos
MX2023005641A (es) Forma de dosificacion en capsula de gelatina blanda de talazoparib.
MX2022010593A (es) Composiciones tópicas de diclofenaco y métodos.
MX2022002038A (es) Composicion farmaceutica para el tratamiento del insomnio.